“The notion that this is a normal market, where competition will work, is foolhardy,” he said.
Morning Consult 03/07/2016
Peter Bach and the Drug Pricing Problem
The problem with Martin Shkreli is he's too good at what he does.
"He's just a distillation of the industry behavior in its purest form. It's all about the stockholders."
In this in-depth article, Dr. Peter Bach describes how the market for pharmaceuticals is unlike other markets.
Read the full article here.